MOREPENLABPharmaceuticals
Morepen Laboratories Ltd — Cash Flow Statement
₹33.68
-2.22%
Morepen Laboratories Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -182.18 Cr | -7.96 Cr | -137.14 Cr | -127.61 Cr | — |
| Issuance Of Debt | 50.39 Cr | 3.84 Cr | — | — | — |
| Issuance Of Capital Stock | 190.73 Cr | 0.00 | 137.15 Cr | 52.50 Cr | — |
| Capital Expenditure | -214.24 Cr | -81.34 Cr | -45.97 Cr | -67.37 Cr | — |
| End Cash Position | 27.38 Cr | 16.95 Cr | 21.67 Cr | 15.80 Cr | — |
| Beginning Cash Position | 16.95 Cr | 21.67 Cr | 15.80 Cr | 41.39 Cr | — |
| Changes In Cash | 10.44 Cr | -4.72 Cr | 5.86 Cr | -25.58 Cr | — |
| Financing Cash Flow | 299.89 Cr | 5.20 Cr | 143.54 Cr | 66.33 Cr | — |
| Net Other Financing Charges | 41.40 Cr | 5.08 Cr | 1.78 Cr | 12.31 Cr | — |
| Interest Paid Cff | -8.34 Cr | -3.71 Cr | -1.98 Cr | — | -1.79 Cr |
| Net Common Stock Issuance | 190.73 Cr | 0.00 | 137.15 Cr | 52.50 Cr | — |
| Common Stock Issuance | 190.73 Cr | 0.00 | 137.15 Cr | 52.50 Cr | — |
| Net Issuance Payments Of Debt | 50.39 Cr | 3.84 Cr | 6.60 Cr | 1.52 Cr | — |
| Net Short Term Debt Issuance | 28.00 Cr | 1.40 Cr | 6.98 Cr | 1.03 Cr | — |
| Short Term Debt Issuance | 28.00 Cr | 1.40 Cr | — | — | — |
| Net Long Term Debt Issuance | 22.39 Cr | 2.43 Cr | -0.39 Cr | 0.49 Cr | — |
| Long Term Debt Issuance | 22.39 Cr | 2.43 Cr | — | — | — |
| Investing Cash Flow | -321.51 Cr | -83.30 Cr | -46.51 Cr | -31.68 Cr | — |
| Net Other Investing Changes | -23.64 Cr | -0.72 Cr | -0.54 Cr | 33.98 Cr | — |
| Net Investment Purchase And Sale | -83.68 Cr | -1.30 Cr | 0.00 | 1.54 Cr | — |
| Purchase Of Investment | -83.68 Cr | -1.30 Cr | — | — | — |
| Net Intangibles Purchase And Sale | -90.20 Cr | -9.95 Cr | -10.35 Cr | -21.92 Cr | — |
| Purchase Of Intangibles | -90.20 Cr | -9.95 Cr | -10.35 Cr | -21.92 Cr | — |
| Net PPE Purchase And Sale | -123.98 Cr | -71.33 Cr | -35.62 Cr | -45.28 Cr | — |
| Sale Of PPE | 0.05 Cr | 0.05 Cr | 0.00 | 0.17 Cr | — |
| Purchase Of PPE | -124.03 Cr | -71.38 Cr | -35.62 Cr | -45.45 Cr | — |
| Operating Cash Flow | 32.06 Cr | 73.37 Cr | -91.17 Cr | -60.24 Cr | — |
| Taxes Refund Paid | -37.15 Cr | -38.12 Cr | -16.55 Cr | -24.93 Cr | — |
| Change In Working Capital | -123.69 Cr | -58.12 Cr | -158.28 Cr | -181.47 Cr | — |
| Change In Other Current Liabilities | 58.39 Cr | 79.48 Cr | -142.28 Cr | 51.63 Cr | — |
| Change In Inventory | -51.37 Cr | -19.71 Cr | 46.97 Cr | -100.53 Cr | — |
| Change In Receivables | -130.71 Cr | -117.89 Cr | -62.97 Cr | -132.57 Cr | — |
| Other Non Cash Items | 8.34 Cr | 3.71 Cr | 1.98 Cr | -7.37 Cr | — |
| Depreciation And Amortization | 28.98 Cr | 33.47 Cr | 27.93 Cr | 27.64 Cr | — |
| Depreciation | 28.98 Cr | 33.47 Cr | 12.40 Cr | 27.64 Cr | — |
| Pension And Employee Benefit Expense | 0.25 Cr | -2.75 Cr | -2.01 Cr | -0.46 Cr | — |
| Net Foreign Currency Exchange Gain Loss | 0.06 Cr | 0.23 Cr | 0.00 | — | — |
| Gain Loss On Sale Of PPE | 0.15 Cr | 0.00 | 0.00 | -0.36 Cr | — |
| Net Income From Continuing Operations | 155.11 Cr | 135.42 Cr | 55.76 Cr | 126.70 Cr | — |
| Amortization Cash Flow | — | 15.78 Cr | 15.53 Cr | — | — |
| Change In Payable | — | — | — | 2.48 Cr | — |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Morepen Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.